Therapeutic Predictor of Disodium Eromoglycate(DSCG) on Bronchial Asthma / 대한내과학회지

ABSTRACT

OBJECTIVES: Although DSCG protects against the stimuli of various bronchoconstictor, such as exercise, it is not effective to all patients. There seems to be no therapeutic predictor that determines effectiveness of DSCG on bronchial asthma. Although it is commonly assumed that children with predominantly allergic asthma have a better response to DSCG therapy than adult patient, this has not been convincingly demonstrated, and even adult with late onset nonallergic asthma may benefit. In this study, we evaluated the factors that potentially influenced the ability of DSCG to reduce bronchial hyperresponsibility. METHODS: The treatment groups were sub-divide into effective group(n=14) and ineffective group(n=6) on the basis of significant improvement of followedup PC20 after long term therapy of DSCG. We compared clinical and laboratory data and pulmonary function test between two groups. RESULTS: 1) Disease durtion and pre-treatment pulmonary function (FEV1% predicted, FVC% predicted value) may play a role in determining effectiveness of DSCG on bronchial asthma(p0.05). CONCLUSION: These results show that DSCG is effective in adult chronic asthma and early administration of DSCG, good pulmonary function test and allergic rhinitis history may lead to more favorable outcome.